Darleukin (L19IL2): A Comprehensive Monograph on a Tumor-Targeted Immunocytokine

Executive Summary

Darleukin, identified by the research code L19IL2 and the DrugBank ID DB17157, is an investigational, fully-human immunostimulatory biopharmaceutical. It is classified as an immunocytokine, a type of recombinant fusion protein engineered to overcome the limitations of systemic cytokine therapy. Darleukin consists of two key components: the human cytokine interleukin-2 (IL-2) and the human L19 antibody. The L19 antibody moiety is designed to specifically target the extra-domain B (EDB) of fibronectin, a protein isoform that is highly expressed within the tumor microenvironment (TME) and associated with angiogenesis, but is largely absent in healthy, mature tissues. This targeted delivery mechanism is central to Darleukin's therapeutic strategy, enabling the concentration of IL-2's potent immunostimulatory effects directly at the site of disease, thereby enhancing its therapeutic index while mitigating the severe systemic toxicities associated with high-dose, untargeted IL-2 administration.

The mechanism of action involves the selective localization of Darleukin within the tumor stroma, followed by the activation of a robust anti-tumor immune response. The IL-2 payload stimulates the proliferation and activation of tumor-specific cytotoxic CD8+ T lymphocytes and Natural Killer (NK) cells, which are critical effectors in the eradication of cancer cells. Clinical investigations, particularly with intralesional administration, have demonstrated that this localized immune activation can translate into a systemic anti-tumor effect, leading to the regression of non-injected metastatic lesions.

Darleukin has undergone extensive clinical evaluation across a range of solid tumors, both as a monotherapy and in combination with other therapeutic modalities. The most advanced clinical programs have focused on skin cancers and non-small cell lung cancer (NSCLC). In melanoma, Darleukin is a key component of the combination product Nidlegy™ (also known as Daromun), where it is co-administered with L19TNF (Onfekafusp alfa). A pivotal Phase III trial (NCT03567889) evaluating Nidlegy™ as a neoadjuvant treatment for resectable Stage IIIB/C melanoma met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in recurrence-free survival compared to surgery alone. In NSCLC, the ongoing Phase II IMMUNOSABR trial (NCT03705403) is exploring a tri-modal therapy combining Darleukin with stereotactic ablative radiotherapy (SABR) and anti-PD-1 therapy, testing a novel "in-situ vaccination" strategy.

The pharmacological profile of Darleukin is characterized by a terminal half-life of approximately 2-3 hours following intravenous administration. Its safety profile is highly dependent on the route of administration. Intravenous delivery is associated with manageable, IL-2-related toxicities at the recommended dose of 22.5 million international units (Mio IU), whereas intralesional administration exhibits a markedly improved safety profile, with adverse events being predominantly low-grade and localized to the injection site.

Developed by the Italian-Swiss biotechnology company Philogen S.p.A., Darleukin is part of a broader platform of L19-based targeted therapeutics. Philogen has entered into a strategic partnership with Sun Pharmaceutical Industries for the commercialization of Nidlegy™ in Europe, Australia, and New Zealand. A Marketing Authorization Application (MAA) was submitted to the European Medicines Agency (EMA) in June 2024 but was later voluntarily withdrawn due to timing constraints related to data availability, with the stated intent to resubmit. This positions Darleukin, particularly as part of Nidlegy™, as a promising late-stage asset with the potential to address significant unmet needs in onco-dermatology and beyond.

Introduction to Darleukin: Engineering a Targeted Cytokine Therapy

The Rationale for Antibody-Cytokine Fusions: Overcoming the Limitations of Systemic IL-2

The therapeutic potential of harnessing the immune system to combat cancer has been recognized for decades, with interleukin-2 (IL-2) being one of the first and most potent immunomodulatory agents to demonstrate clinical efficacy. Recombinant IL-2 (aldesleukin) gained regulatory approval from the U.S. Food and Drug Administration (FDA) for the treatment of metastatic renal cell carcinoma in 1992 and metastatic melanoma in 1998, based on its ability to induce durable, long-term complete responses in a small but significant subset of patients.[1] IL-2 functions as a crucial regulator of the immune system, promoting the proliferation, differentiation, and cytotoxic activity of key effector cells, including T cells and Natural Killer (NK) cells.[4]

Despite this proven efficacy, the clinical application of high-dose IL-2 has been severely constrained by its profound and often life-threatening systemic toxicities.[1] When administered systemically, IL-2's pleiotropic effects are not confined to the tumor microenvironment. Its widespread activation of the immune system can lead to a cascade of adverse events, most notably a vascular leak syndrome characterized by hypotension, intravascular depletion, and multi-organ compromise.[3] Other common toxicities include severe flu-like symptoms, fever, and in extreme cases, coma.[7] These dose-limiting toxicities necessitate administration in specialized inpatient settings and have restricted the use of high-dose IL-2 to a highly selected population of young, physically fit patients with excellent organ function.[1]

To address this fundamental challenge of separating efficacy from toxicity, researchers developed the concept of antibody-cytokine fusion proteins, also known as immunocytokines.[8] This strategy is based on a simple yet powerful principle: physically linking a potent cytokine payload to a monoclonal antibody that specifically recognizes an antigen overexpressed on tumor cells or within the tumor microenvironment.[1] This molecular engineering creates a bifunctional agent designed to act as a "guided missile," selectively delivering the cytokine to the site of disease.[11] By concentrating the pro-inflammatory activity of IL-2 within the tumor, immunocytokines aim to achieve high local concentrations necessary for a robust anti-tumor effect while minimizing systemic exposure and its associated toxicities. This approach is intended to dramatically improve the therapeutic index of the cytokine, making it a safer and more broadly applicable treatment modality.[9]

Darleukin (L19IL2): A Novel Biopharmaceutical Construct

Darleukin is a clinical-stage immunocytokine that embodies the principles of targeted cytokine therapy.[12] It is a fully-human, immunostimulatory product identified by the research code L19IL2 and the proposed International Nonproprietary Name (INN) Bifikafusp alfa.[12] As a biotech drug, Darleukin is a recombinant fusion protein, meticulously engineered to combine the tumor-targeting capabilities of an antibody with the immune-activating function of a cytokine.[12] The information presented in some database entries, such as one suggesting it is a form of erythropoietin, is erroneous and inconsistent with the extensive body of primary research and clinical trial data, which unequivocally define Darleukin as the L19IL2 fusion protein.[12]

The L19 Antibody and its Target: The Extra-Domain B (EDB) of Fibronectin as a Marker of Angiogenesis

The specificity of Darleukin is conferred by its antibody component, the human L19 antibody.[12] This antibody was selected for its high-affinity and highly specific recognition of the extra-domain B (EDB) of fibronectin.[1] Fibronectin is a ubiquitous glycoprotein found in the extracellular matrix, but the EDB isoform represents a specific, alternatively spliced variant that serves as a compelling target for cancer therapy.[1]

The EDB domain is a 91-amino acid sequence that is inserted into the fibronectin molecule primarily during processes of active tissue remodeling, such as embryogenesis, wound healing, and, critically, tumor-associated angiogenesis and invasion.[10] While EDB-containing fibronectin is abundant in the neovasculature and stroma of a wide array of malignant tumors, it is virtually absent from the mature, quiescent vasculature and healthy tissues of adults, with the exception of the female reproductive tract.[1] This stark differential expression profile makes EDB an excellent molecular marker of malignancy and ongoing angiogenesis.[1] The L19 antibody binds to EDB with picomolar affinity, ensuring a strong and durable anchor for the IL-2 payload within the tumor microenvironment, facilitating selective drug accumulation and prolonged residence time at the site of action.[10]

Molecular Profile and Immunological Mechanism of Action

Structural Composition: The L19 Diabody and the IL-2 Payload

Darleukin's molecular architecture is a key determinant of its function. It is a fully human recombinant fusion protein where the human cytokine IL-2 is genetically fused to the L19 antibody.[12] The L19 antibody component is not a full-length immunoglobulin G (IgG) but is instead engineered into a smaller, non-covalent, homodimeric format known as a "diabody".[19]

A diabody is constructed from two single-chain variable fragments (scFv). Each scFv consists of the variable heavy () and variable light () domains of the antibody, connected by a short peptide linker. The linker is deliberately designed to be too short to allow pairing between the  and  domains on the same chain. Consequently, the domains of one chain are forced to pair with the complementary domains of a second chain, resulting in the formation of a non-covalent dimer with two antigen-binding sites.[22] This bivalent structure provides high binding avidity to the target antigen, EDB-fibronectin, which contributes to the prolonged retention of Darleukin within the tumor.[19] The development of this specific format reflects an ongoing effort to optimize the biopharmaceutical properties of the delivery vehicle. Research by the developing group has also explored alternative molecular arrangements, such as a single-chain diabody format (termed L19L19-IL2), in a continuous effort to improve tumor-homing characteristics and overall therapeutic performance.[20]

Pharmacodynamics: From Tumor Microenvironment Localization to Immune Cell Activation

The primary pharmacodynamic effect of Darleukin is the targeted delivery and subsequent accumulation of bioactive IL-2 within the tumor microenvironment.[12] Following administration, the L19 diabody moiety of Darleukin binds with high affinity to EDB-fibronectin present in the tumor stroma and surrounding the neovasculature.[1] This specific binding acts as a molecular anchor, leading to a selective concentration of the IL-2 payload at the site of the disease.[7]

This targeted accumulation achieves two critical therapeutic goals. First, it generates high intra-tumoral concentrations of IL-2, which are necessary to overcome the immunosuppressive nature of the TME and effectively stimulate an anti-cancer immune response.[7] Second, by sequestering the IL-2 at the tumor site, it minimizes the peak levels of the cytokine in systemic circulation, which is the primary driver of the severe toxicities associated with untargeted IL-2 therapy.[10] Studies have shown that the residence time of L19-based fusion proteins within tumor lesions is substantially longer (≥72 hours) compared to that of untargeted cytokines, which are cleared from circulation much more rapidly (<24 hours).[6] This prolonged local exposure enhances the duration and intensity of the immunostimulatory signal where it is most needed.

Induction of Local and Systemic Anti-Tumor Immunity: The Role of T-Cells and NK Cells

Once localized within the TME, the IL-2 component of Darleukin exerts its potent anti-cancer activity by modulating the local immune landscape. It functions as a powerful growth and activation signal for key immune effector cells, most notably tumor-specific cytotoxic CD8+ T lymphocytes (CTLs) and Natural Killer (NK) cells.[4] The high concentration of IL-2 at the tumor site promotes the in-situ recruitment, proliferation, and activation of these cells, effectively transforming an immunosuppressive or "cold" TME into an inflamed or "hot" environment conducive to tumor cell killing.[24]

The essential role of this immune-mediated mechanism has been validated in preclinical models. For instance, in orthotopic models of pancreatic cancer, the anti-tumor efficacy of L19IL2 was completely abolished when NK cells were depleted from the host, confirming that these cells are indispensable for the drug's therapeutic effect.[10] This activation of innate (NK cells) and adaptive (T cells) immunity leads to the direct killing of cancer cells within the treated lesion.[12]

A pivotal finding that elevates the therapeutic potential of this approach beyond simple local control is the induction of a systemic anti-tumor immune response following local administration. The challenge with systemic IL-2 is its toxicity. Targeted delivery via the L19 antibody is the proposed solution. The most direct and efficient method of targeted delivery is intralesional injection, which maximizes local concentration while drastically minimizing systemic exposure. However, for a patient with metastatic disease, a treatment that only affects the injected tumors would be of limited value. The repeated observation from clinical studies that the intralesional injection of Darleukin (often in combination with L19TNF) into accessible tumors leads to the regression and complete response of distant, non-injected metastases is therefore a fundamentally important result.[19] This phenomenon, known as the abscopal effect, demonstrates that the intense, localized immune activation within the treated lesion is sufficient to prime and educate the immune system, generating a population of effector cells and a durable immune memory that can patrol the body and eradicate cancer systemically.[8] This validation of a systemic effect from a local treatment underpins the entire strategic rationale for using intralesional Nidlegy™ (which contains Darleukin) as a neoadjuvant therapy for patients with regional metastatic melanoma, aiming not just to shrink the injected tumors but to reduce the risk of future recurrence throughout the body.

Comprehensive Review of Clinical Development

Early Phase Evaluation: Dose Escalation, Safety, and Initial Signals of Efficacy in Solid Tumors

The clinical development of Darleukin (L19IL2) began with Phase I and Phase I/II studies designed to establish the safety, tolerability, pharmacokinetics, and preliminary efficacy of the intravenously administered immunocytokine in patients with a variety of advanced solid tumors.[26] These initial dose-escalation trials were crucial for defining the therapeutic window of the drug.

In a key study involving patients with recurrent or refractory solid tumors, L19IL2 was administered via intravenous infusion on days 1, 3, and 5 of a 21-day cycle, with doses escalating from 5 to 30 million international units (Mio IU) of IL-2 equivalent.[26] The dose of 30 Mio IU was found to be excessively toxic, with dose-limiting toxicities including hypotension requiring vasopressor support and acute renal failure.[26] Consequently, the maximum tolerated dose (MTD) and the recommended Phase II dose (RD) for subsequent studies was established at 22.5 Mio IU.[26] At this dose, toxicities were found to be manageable, reversible, and consistent with the known effects of systemic IL-2, with no treatment-related deaths reported.[26]

These early trials also provided the first signals of clinical activity. While objective responses were not common, a significant proportion of patients, particularly those with metastatic renal cell carcinoma (RCC), achieved stable disease.[26] In a cohort of 18 patients with advanced RCC, 13 (81%) experienced stable disease after treatment.[27] This encouraging signal in an immunologically responsive tumor type provided the initial rationale for further development, although the program for RCC was later discontinued in favor of other indications.[29] These foundational studies successfully demonstrated that L19IL2 could be safely administered and confirmed its biological activity, paving the way for more targeted investigations in specific cancer types.

Table 1: Summary of Key Clinical Trials for Darleukin (L19IL2) and its Combinations

Trial ID	Title / Brief Summary	Phase	Indication(s)	Intervention(s)	Route	Status	Key Snippet References
NCT03567889	Efficacy of Daromun (L19IL2+L19TNF) Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C Melanoma Patients	3	Stage IIIB/C Melanoma	Daromun (L19IL2 + L19TNF) + Surgery vs. Surgery alone	Intratumoral	Recruiting	8
NCT03705403	IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) in Metastatic Non-Small Cell Lung Cancer	2	Metastatic NSCLC	Darleukin (L19IL2) + SABR +/- anti-PD-1 therapy	Intravenous	Terminated	12
NCT01055522	Study of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma	2	Metastatic Melanoma	Darleukin (L19IL2) + Dacarbazine (DTIC)	Intravenous	Unknown	38
NCT04362722	Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients	2	Basal Cell Carcinoma (BCC), Cutaneous Squamous Cell Carcinoma (cSCC)	Daromun (L19IL2 + L19TNF)	Intratumoral	Recruiting	13
NCT05329792	A Phase II Study of L19IL2/L19TNF in Patients With Skin Cancers Amenable to Intralesional Treatment (IntriNSiC)	2	BCC, cSCC, Merkel Cell Carcinoma, Kaposi Sarcoma, CTCL, etc.	Daromun (L19IL2 + L19TNF)	Intratumoral	Unknown	14
NCT02076633	Intratumoral Administration of L19IL2/L19TNF	2	Malignant Melanoma	L19IL2 and/or L19TNF	Intratumoral	Completed	49
NCT06284590	Study of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma	2	Unresectable Melanoma	L19IL2 and/or L19TNF + Pembrolizumab	Intratumoral / IV	Recruiting	52

Pivotal Investigations in Malignant Melanoma

Malignant melanoma, a highly immunogenic tumor, has been the primary focus for the late-stage clinical development of Darleukin, both as a single agent and as a component of combination therapies.

Neoadjuvant Intralesional Therapy: The Nidlegy™/Daromun (L19IL2 + L19TNF) Program (NCT03567889)

The most advanced and commercially significant program involves the combination of L19IL2 (Darleukin/Bifikafusp alfa) with a second immunocytokine, L19TNF (Onfekafusp alfa/Fibromun). This combination product is known as Nidlegy™ or Daromun.[17] Preclinical studies demonstrated a remarkable synergistic effect between the two agents, leading to complete tumor remissions in animal models.[19] L19TNF targets the pro-inflammatory cytokine Tumor Necrosis Factor (TNF) to the tumor, complementing the T-cell and NK-cell activating properties of L19IL2.

This preclinical rationale led to the initiation of the PIVOTAL trial (NCT03567889), a large, randomized, controlled Phase III study. The trial was designed to evaluate the efficacy of Nidlegy™ as a neoadjuvant (pre-surgery) therapy for patients with clinical Stage IIIB/C melanoma with injectable lesions who are candidates for complete surgical resection.[8] Patients were randomized in a 1:1 ratio to receive either four weekly intratumoral injections of Nidlegy™ followed by surgery, or to proceed directly to surgery (the standard of care).[30] The primary objective was to determine if the neoadjuvant treatment could improve recurrence-free survival (RFS).[31]

In 2023, it was announced that the PIVOTAL trial successfully met its primary endpoint. The results, presented at the American Society of Clinical Oncology (ASCO) annual meeting in 2024, showed a statistically significant and clinically meaningful benefit for the Nidlegy™ arm. The neoadjuvant treatment resulted in a 41% reduction in the risk of disease recurrence or death compared to surgery alone.[8] This landmark result positions Nidlegy™ as a potential first-in-class neoadjuvant immunotherapy for this patient population, addressing a significant unmet medical need.[54]

Combination with Chemotherapy in Metastatic Disease (Dacarbazine, NCT01055522)

Prior to the focus on neoadjuvant therapy, Darleukin was evaluated in the metastatic setting in combination with standard chemotherapy. A randomized Phase II clinical trial (NCT01055522) was conducted in patients with advanced (Stage IV) metastatic melanoma.[39] The study compared the combination of intravenous L19IL2 (at the recommended dose of 22.5 Mio IU) plus dacarbazine (DTIC) against DTIC monotherapy.[38]

The results of this trial demonstrated a clear benefit for the combination therapy. Patients receiving L19IL2 plus DTIC had a statistically significant improvement in both overall response rate (ORR) and median progression-free survival (PFS) compared to those who received DTIC alone.[15] These findings confirmed the clinical activity of L19IL2 in melanoma and provided evidence of its synergistic potential with chemotherapy.

Synergy with Immune Checkpoint Inhibition (Pembrolizumab)

Building on its immunomodulatory mechanism, Darleukin and the Nidlegy™ combination are being actively investigated alongside immune checkpoint inhibitors (ICIs). A strong rationale exists for combining a potent immune activator like L19IL2 with an agent that blocks inhibitory pathways like PD-1.[11] This is particularly relevant for patients with unresectable melanoma who have progressed on or are resistant to prior ICI therapy, a growing population with limited options.[11]

Ongoing Phase II clinical trials, such as NCT06284590, are evaluating the intralesional administration of L19IL2, L19TNF, or the Nidlegy™ combination concurrently with systemic administration of the anti-PD-1 antibody KEYTRUDA® (pembrolizumab).[11] The goal of these studies is to determine if the localized immunostimulation provided by the immunocytokines can overcome resistance to PD-1 blockade and re-sensitize the tumors to checkpoint inhibition, thereby generating meaningful clinical responses in this difficult-to-treat patient population.[11]

Application in Non-Small Cell Lung Cancer (NSCLC)

The IMMUNOSABR Trial (NCT03705403): A Tri-modal Approach with Radiotherapy and PD-1 Blockade

Darleukin's development has expanded beyond skin cancers into other solid tumors, with a significant program in metastatic non-small cell lung cancer (NSCLC).[12] The cornerstone of this effort is the IMMUNOSABR trial (NCT03705403), an investigator-driven, multi-center, randomized Phase II study.[12] This trial is designed to evaluate a novel, tri-modal therapeutic strategy combining Darleukin with Stereotactic Ablative Radiotherapy (SABR) and anti-PD-1 therapy.[12]

The trial planned to enroll 126 patients with oligometastatic (≤5 metastases) or polymetastatic (6-10 metastases) NSCLC and randomize them to a control arm (standard of care) or an experimental arm receiving L19IL2 following radiotherapy.[34] The primary endpoint of the study is progression-free survival (PFS).[35] The trial was listed as terminated because it was not transitioning to the new Clinical Trial Regulation (CTR) in the EU, but the underlying scientific question remains highly relevant.[56]

The design of the IMMUNOSABR trial represents a clinical test of the "in-situ vaccination" hypothesis, a major paradigm in modern immuno-oncology. The challenge in treating many solid tumors, including a subset of NSCLC, is their "cold" or non-immunogenic nature, meaning they lack the pre-existing immune infiltrate necessary for treatments like checkpoint inhibitors to be effective. The in-situ vaccination strategy aims to convert these "cold" tumors into "hot" ones. In this therapeutic model, SABR acts as the first step, inducing immunogenic cell death. This process kills tumor cells in a manner that causes them to release a trove of tumor-associated antigens, effectively creating a personalized, in-situ "vaccine".[34] Darleukin (L19IL2) then functions as the second step, serving as a potent, targeted adjuvant. By concentrating the powerful immunostimulatory signal of IL-2 directly at the site of antigen release, it amplifies the subsequent immune response, promoting the activation and expansion of T-cells specific to those newly released antigens. The third component, anti-PD-1 therapy, acts to remove the inhibitory "brakes" on these newly activated T-cells, allowing them to carry out their cytotoxic function more effectively.[12] Therefore, the outcome of this trial carries implications beyond just the development of Darleukin for NSCLC. It serves as a clinical proof-of-concept for a therapeutic strategy that could potentially be applied to a wide range of immunologically cold solid tumors, by combining targeted cytokine delivery with radiotherapy to initiate and potentiate a powerful, systemic anti-tumor immune response.

Emerging Roles in Non-Melanoma Skin Cancers (NMSC)

Phase II Investigations in Basal Cell (BCC) and Cutaneous Squamous Cell Carcinoma (cSCC)

Inspired by the strong performance of intralesional Nidlegy™ in melanoma, Philogen has initiated Phase II clinical programs to investigate its efficacy and safety in other common skin cancers, specifically high-risk, locally advanced basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC).[13] These cancers, while often curable with surgery, can become challenging to treat when they are large, located in cosmetically sensitive areas, or recur after initial treatment, creating a medical need for effective non-invasive therapies.[45]

Two key trials in this program are NCT04362722 and NCT05329792. The NCT04362722 study is a Phase II trial specifically designed to evaluate intratumoral Nidlegy™ in patients with injectable lesions of high-risk BCC or cSCC who are not eligible for or refuse surgery.[13] In this study, patients receive four weekly intralesional injections of a mixture containing 6.5 Mio IU of L19IL2 and 200 µg of L19TNF.[45] The NCT05329792 trial is a broader "basket" study investigating the same treatment in a variety of skin cancers amenable to intralesional injection, including BCC, cSCC, Merkel cell carcinoma, and Kaposi sarcoma, among others.[14] These trials aim to leverage the favorable safety profile and demonstrated efficacy of local Nidlegy™ administration to provide a new therapeutic option for patients with difficult-to-treat NMSC.

Integrated Pharmacological and Safety Profile

Pharmacokinetics: Absorption, Distribution, and Elimination Characteristics

The pharmacokinetic (PK) profile of Darleukin has been characterized in early-phase clinical trials following intravenous administration.[26] A key finding from these studies is that the pharmacokinetics of L19IL2 are dose-proportional across the clinically tested range of 5 to 30 Mio IU.[28]

The defining PK parameter for L19IL2 is its terminal half-life, which has been reported to be approximately 2-3 hours.[28] This relatively short half-life is characteristic of antibody fragments like scFvs and diabodies, which lack the Fc region responsible for neonatal Fc receptor (FcRn)-mediated recycling that extends the half-life of full-length IgG antibodies to several weeks.[9] While a shorter half-life can be a disadvantage for systemic therapies requiring sustained exposure, it can be beneficial for a potent agent like a cytokine fusion, as it may help to limit the duration of systemic side effects.

The distribution of the drug is governed by its targeting moiety. The L19 antibody's high affinity for EDB-fibronectin leads to its preferential accumulation and retention within the tumor microenvironment, a phenomenon known as target-mediated drug disposition (TMDD).[6] This results in a prolonged residence time in the tumor (≥72 hours) relative to its rapid clearance from the circulation, which is the central principle behind its improved therapeutic index.[6] The development of human anti-fusion protein antibodies (HAFA) has been monitored in clinical trials, with early data suggesting only a weak induction in a subset of patients, indicating a potentially low immunogenicity risk.[26]

Safety and Tolerability Analysis Across Clinical Trials

The safety and tolerability profile of Darleukin is critically dependent on the route of administration, with a clear and significant distinction between intravenous and intralesional delivery.

Intravenous Administration

When administered intravenously, Darleukin's safety profile is largely reflective of the systemic effects of its IL-2 payload. At the recommended Phase II dose of 22.5 Mio IU, the treatment is considered to have a manageable and reversible toxicity profile.[28] Common adverse events are consistent with IL-2-related immune stimulation and include constitutional symptoms such as low-grade fever, chills, fatigue, and pruritus.[1] Laboratory findings typically show a transient stimulation of immune cell populations, particularly NK cells and T-cell subsets.[26] At doses exceeding the MTD (e.g., 30 Mio IU), more severe, dose-limiting toxicities emerge, including Grade 3 hypotension and acute renal failure, which are hallmarks of severe IL-2 toxicity.[26]

Intralesional Administration

In stark contrast, the intralesional administration of Darleukin, typically as part of the Nidlegy™ combination, exhibits a substantially more favorable safety profile.[25] This route of delivery minimizes systemic exposure, thereby avoiding the most severe IL-2-related toxicities. The vast majority of treatment-related adverse events are low-grade (Grade 1 or 2) and are localized to the site of injection.[19] These local reactions commonly include injection site pain, swelling (edema), and redness (erythema), which are often followed by selective tumor necrosis and ulceration as the treatment takes effect.[1] Systemic side effects are typically mild and transient, such as low-grade fever and headache, which can be managed with standard supportive care like acetaminophen.[25] The excellent tolerability of the intralesional approach is a key advantage that has enabled its successful development in the neoadjuvant setting and in the treatment of non-melanoma skin cancers, where minimizing morbidity is paramount.

Table 2: Consolidated Safety Profile of Darleukin (L19IL2) Administration

Adverse Event Category	Common Adverse Events	Grade (Typical)	Administration Route	Key Snippet References
Injection Site Reactions	Swelling, erythema, pain, necrosis, ulceration	1-2 (occasionally 3)	Intralesional	1
Constitutional Symptoms	Fever, chills, fatigue, headache	1-2	Both (more frequent/severe with IV)	1
Cardiovascular	Hypotension	1-2 (DLT at high IV dose)	Intravenous	26
Renal	Renal failure	DLT at high IV dose	Intravenous	26
Dermatologic	Pruritus, rash	1-2	Both (more frequent with IV)	1
Gastrointestinal	Nausea, vomiting	1-2	Intravenous	59
Immunologic	Transient increase in NK cells and T-cells	N/A (Pharmacodynamic effect)	Intravenous	1

DLT: Dose-Limiting Toxicity

Regulatory and Commercial Landscape

Corporate Strategy: Philogen S.p.A. and the Darleukin Platform

Darleukin is the creation of Philogen S.p.A., an Italian-Swiss clinical-stage biotechnology company with a specialized focus on developing innovative medicines based on tumor-targeting antibodies and small molecule ligands.[11] The company's core strategy revolves around a platform-based approach, leveraging proprietary technologies to discover and develop high-affinity ligands that can selectively deliver potent therapeutic payloads to tissues affected by disease.[11]

The L19 antibody serves as a cornerstone of this platform. Its ability to selectively target the EDB domain of fibronectin, a validated marker of angiogenesis, makes it a versatile vehicle for delivering various active agents to the tumor microenvironment.[11] Philogen has exploited this by creating a pipeline of L19-based immunocytokines, including not only Darleukin (L19IL2) but also Fibromun (L19TNF), which are being developed both as single agents and, most prominently, as the combination product Nidlegy™.[12] This strategy allows the company to explore different biological mechanisms and combination therapies while building upon a well-characterized and clinically validated targeting technology.

Strategic Alliances: The Sun Pharma Partnership for Nidlegy™

To navigate the complex and resource-intensive process of late-stage development and commercialization, Philogen has formed a key strategic alliance with Sun Pharmaceutical Industries, a major multinational pharmaceutical company.[17] In May 2023, the two companies entered into an exclusive distribution, license, and supply agreement for the commercialization of Nidlegy™ in the key territories of Europe, Australia, and New Zealand.[17]

Under the terms of this partnership, the roles and responsibilities are clearly defined. Philogen retains control over the core development aspects, including completing the pivotal clinical trials, pursuing Marketing Authorization with regulatory bodies like the EMA, and handling the manufacturing of commercial supplies.[60] Sun Pharma, with its extensive commercial infrastructure and experience, will be responsible for all commercialization activities within the licensed territories.[60] The agreement is structured as a true partnership, with the two companies sharing the post-commercialization economics in an approximately 50:50 ratio.[60] This collaboration provides Philogen with a powerful commercial partner to maximize the potential of Nidlegy™ in major markets, while allowing it to retain intellectual property rights for other territories and indications.[60]

Regulatory Pathway in Europe: The EMA Marketing Authorization Application for Nidlegy™

Following the positive results from the Phase III PIVOTAL trial, Philogen and Sun Pharma moved swiftly to seek regulatory approval for Nidlegy™. A Marketing Authorization Application (MAA) for Nidlegy™ for the neoadjuvant treatment of locally advanced, fully resectable melanoma was submitted to the European Medicines Agency (EMA) on June 3, 2024, and was subsequently validated by the agency on June 20, 2024, marking the official start of the review process.[61]

However, in a subsequent development, Philogen announced the voluntary withdrawal of the MAA from the EMA.[62] It is critical to note that this decision was not prompted by concerns regarding the drug's efficacy or safety. Instead, the company cited "timing constraints related to the availability of critical regulatory data" as the reason for the withdrawal.[62] This suggests a procedural or data-packaging issue rather than a fundamental flaw in the clinical data package.

Philogen has publicly stated its commitment to resubmitting an updated application as expeditiously as possible and remains in close dialogue with the EMA.[62] This positions the event as a regulatory delay rather than a termination of the program. Assuming a timely resubmission, a potential EMA approval for Nidlegy™ could still be anticipated, though the timeline has been shifted, likely into 2025 or beyond, depending on the length of the new review cycle.[54]

Synthesis and Future Directions

Darleukin's Position in the Immuno-Oncology Paradigm

Darleukin (L19IL2) represents a distinct and complementary approach within the broader field of cancer immunotherapy. Unlike immune checkpoint inhibitors, which function by removing the brakes on a pre-existing immune response, Darleukin is a direct and potent immune activator. Its primary role is to "press the accelerator" of the immune system, but in a highly targeted manner.

The key differentiator for Darleukin is its ability to initiate and amplify a de novo immune response directly within the tumor microenvironment. This mechanism makes it particularly valuable for treating immunologically "cold" tumors—those lacking the T-cell infiltrate necessary for checkpoint inhibitors to be effective. By delivering a powerful IL-2 signal to the tumor, Darleukin can transform the local immune landscape, recruiting and activating the very effector cells that are needed for tumor destruction. This positions it not as a competitor to checkpoint inhibitors, but as a highly synergistic partner. The combination of a potent activator (Darleukin) with a brake-releasing agent (e.g., an anti-PD-1 antibody) has the potential to generate more profound and durable anti-tumor responses than either agent could achieve alone. This is the core rationale behind the ongoing combination trials in melanoma and the tri-modal approach being tested in NSCLC.

Potential for Platform Expansion and Future Combination Strategies

The success of Darleukin validates the underlying L19 targeting platform, opening up significant opportunities for future expansion. The L19 antibody has proven to be an effective and safe vehicle for delivering potent payloads to the tumor site. This modularity allows for the potential development of new fusion proteins, where different cytokines, chemokines, or other therapeutic agents could be fused to the L19 moiety to address different biological pathways or tumor types.

Looking ahead, the combination potential of Darleukin extends beyond the current clinical investigations. Given its mechanism of action, synergistic effects could be explored with a wide range of other therapeutic modalities. This includes other immune agonists (e.g., STING agonists, TLR agonists), targeted therapies that may increase tumor antigenicity, and adoptive cell therapies (e.g., CAR-T or TIL therapy), where the localized IL-2 signal from Darleukin could enhance the persistence and function of the engineered immune cells within the solid tumor microenvironment. The strong preclinical and emerging clinical data for combining Darleukin with radiotherapy also suggests a broad applicability of this strategy across many solid tumors where radiation is a standard component of care.

Key Challenges and Opportunities in Late-Stage Development and Commercialization

As Darleukin and its combination product Nidlegy™ advance toward potential commercialization, they face both significant challenges and transformative opportunities.

Challenges:

• Regulatory Navigation: The immediate challenge is the successful resubmission of the Nidlegy™ MAA to the EMA. Ensuring the updated data package meets all regulatory requirements will be critical to minimizing further delays.
• Demonstrating Overall Survival Benefit: While the improvement in recurrence-free survival in the PIVOTAL trial is a major achievement, regulatory agencies and payers in modern oncology often look for a demonstrated benefit in overall survival (OS). Achieving a statistically significant OS benefit can be challenging, especially in neoadjuvant settings where subsequent therapies can confound the results.
• Manufacturing and Logistics: As a biologic fusion protein, Darleukin has a complex manufacturing process. The Nidlegy™ product, which requires the independent manufacturing and subsequent mixing of two distinct immunocytokines (L19IL2 and L19TNF), adds another layer of complexity to the supply chain and administration logistics.

Opportunities:

• First-in-Class Neoadjuvant Therapy: The most significant opportunity is the potential for Nidlegy™ to become the first approved neoadjuvant immunotherapy for resectable Stage III melanoma.[54] This would address a major unmet medical need and establish a new standard of care, offering patients a chance to reduce their risk of recurrence before their disease becomes more advanced.
• Broad Synergy and Market Expansion: The compelling synergistic data with radiotherapy and checkpoint inhibitors creates substantial opportunities for market expansion beyond the initial melanoma indication. Success in trials like IMMUNOSABR could open up large patient populations in NSCLC and other solid tumors.
• Favorable Safety Profile: The excellent safety and tolerability of the intralesional administration route is a major competitive advantage. It could make Nidlegy™ a widely adopted treatment in the onco-dermatology space, particularly for elderly patients or those with comorbidities who may not be candidates for more toxic systemic therapies. This positions Darleukin not just as an effective therapy, but as a safe and accessible one for a broad range of patients.

Works cited

1. Intralesional Treatment of Stage III Metastatic Melanoma Patients ..., accessed October 3, 2025, https://aacrjournals.org/cancerimmunolres/article/2/7/668/467641/Intralesional-Treatment-of-Stage-III-Metastatic
2. Search Orphan Drug Designations and Approvals - FDA, accessed October 3, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=100696
3. Systemic Therapy for Advanced Renal Cell Carcinoma - UroToday, accessed October 3, 2025, https://www.urotoday.com/library-resources/kidney-cancer-today/109243-systemic-therapy-for-advanced-renal-cell-carcinoma.html
4. Efficacy of Anti-Cancer Immune Responses Elicited Using Tumor-Targeted IL-2 Cytokine and Its Derivatives in Combined Preclinical Therapies - MDPI, accessed October 3, 2025, https://www.mdpi.com/2076-393X/13/1/69
5. ANTIBODY-CYTOKINE FUSION PROTEINS FOR TREATMENT OF CANCER: ENGINEERING CYTOKINES FOR IMPROVED EFFICACY AND SAFETY - PMC, accessed October 3, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4354941/
6. Pharmacokinetic analysis. Mean concentrations (±SD) of L19-IL2 - ResearchGate, accessed October 3, 2025, https://www.researchgate.net/figure/Pharmacokinetic-analysis-Mean-concentrations-SD-of-L19-IL2-dacarbazine-and-its_fig2_51746416
7. The immunocytokine L19-IL2: An interplay between radiotherapy ..., accessed October 3, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5889197/
8. Efficacy of Neoadjuvant Intratumoral Darleukin/Fibromun (L19IL2 + L19TNF) in Patients with Clinical Stage IIIB/C Melanoma (Neo-DREAM) | Request PDF - ResearchGate, accessed October 3, 2025, https://www.researchgate.net/publication/358931346_Efficacy_of_Neoadjuvant_Intratumoral_DarleukinFibromun_L19IL2_L19TNF_in_Patients_with_Clinical_Stage_IIIBC_Melanoma_Neo-DREAM
9. Antibody-cytokine fusion proteins: a novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation - PMC, accessed October 3, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6994257/
10. The Targeted Immunocytokine L19-IL2 Efficiently Inhibits the Growth of Orthotopic Pancreatic Cancer - AACR Journals, accessed October 3, 2025, https://aacrjournals.org/clincancerres/article/14/15/4951/72593/The-Targeted-Immunocytokine-L19-IL2-Efficiently
11. Confidential Philogen Announces Clinical Trial Collaboration with MSD, accessed October 3, 2025, https://www.philogen.com/philogen/wp-content/uploads/2023/06/Nidlegy%E2%84%A2_CTCSA_Merck_Press_Release_ENG.pdf
12. Darleukin - Philogen Spa, accessed October 3, 2025, https://www.philogen.com/pipeline/darleukin/
13. Intralesional administration of L19IL2/L19TNF in high-risk locally advanced basal cell carcinoma or cutaneous squamous cell carc, accessed October 3, 2025, https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.TPS9617
14. Study Details | NCT05329792 | L19IL2/L19TNF in Skin Cancer Patients | ClinicalTrials.gov, accessed October 3, 2025, https://clinicaltrials.gov/study/NCT05329792
15. A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients - PubMed, accessed October 3, 2025, https://pubmed.ncbi.nlm.nih.gov/31482307/
16. Browsing Biologic Drugs | DrugBank Online, accessed October 3, 2025, https://go.drugbank.com/biotech_drugs?Allergenics=0&Cell+transplant+therapies=0&Gene+Therapies=0&Nucleic+Acid+Based+Therapies=0&Protein+Based+Therapies=0&Vaccines=0&approved=0&c=name&ca=0&d=up&eu=0&experimental=0&illicit=0&investigational=0&nutraceutical=0&page=45
17. Results of the Phase III PIVOTAL trial of Nidlegy in melanoma to be presented at ASCO 2024 - Philogen, accessed October 3, 2025, https://www.philogen.com/philogen/wp-content/uploads/2024/05/240529_Press_release_PIVOTAL_ASCO_FINAL.pdf
18. What is Darleukin/fibromun used for? - Patsnap Synapse, accessed October 3, 2025, https://synapse.patsnap.com/article/what-is-darleukinfibromun-used-for
19. Intralesional administration of L19-IL2/L19-TNF in stage III or stage ..., accessed October 3, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11028725/
20. A novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo, accessed October 3, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7566808/
21. A novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo - ETH Research Collection, accessed October 3, 2025, https://www.research-collection.ethz.ch/items/45cc534d-e139-4769-9a34-350cc51005c6
22. David vs. Goliath: The Structure, Function, and Clinical Prospects of Antibody Fragments, accessed October 3, 2025, https://www.mdpi.com/2073-4468/8/2/28
23. Format engineering and in vivo validation of novel antibody-fusion proteins for cancer therapy - iris@unitn, accessed October 3, 2025, https://iris.unitn.it/retrieve/handle/11572/323259/506614/Riccardo_Corbellari_PhD_Thesis.pdf
24. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy - Frontiers, accessed October 3, 2025, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2018.02905/full
25. Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study - ResearchGate, accessed October 3, 2025, https://www.researchgate.net/publication/276360870_Intralesional_administration_of_L19-IL2L19-TNF_in_stage_III_or_stage_IVM1a_melanoma_patients_results_of_a_phase_II_study
26. A dose finding pharmacokinetic study of the tumor-targeting human L19-IL2 monoclonal antibody-cytokine fusion protein in patients with advanced solid tumors | Journal of Clinical Oncology - ASCO Publications, accessed October 3, 2025, https://ascopubs.org/doi/10.1200/jco.2007.25.18_suppl.3057
27. Phase I/II study of the tumor-targeting human L19-IL2 monoclonal antibody-cytokine fusion protein in patients with advanced renal cell carcinoma - ASCO Publications, accessed October 3, 2025, https://ascopubs.org/doi/10.1200/jco.2008.26.15_suppl.16032
28. The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma - ResearchGate, accessed October 3, 2025, https://www.researchgate.net/publication/46009081_The_tumour-targeting_human_L19-IL2_immunocytokine_Preclinical_safety_studies_phase_I_clinical_trial_in_patients_with_solid_tumours_and_expansion_into_patients_with_advanced_renal_cell_carcinoma
29. Darleukin by Philogen for Non-Small Cell Lung Cancer: Likelihood of Approval, accessed October 3, 2025, https://www.pharmaceutical-technology.com/data-insights/darleukin-philogen-non-small-cell-lung-cancer-likelihood-of-approval/
30. Neoadjuvant Daromun + Surgery... | Clinical Trials at ... - Duke Health, accessed October 3, 2025, https://www.dukehealth.org/clinical-trials/directory/pro00110577
31. Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C Melanoma Patients - Clinical Trial Finder, accessed October 3, 2025, https://trials.braintumor.org/trials/NCT03567889
32. Nidlegy TM - Philogen, accessed October 3, 2025, https://www.philogen.com/pipeline/nidlegytm/
33. Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C Melanoma Patients | MedPath, accessed October 3, 2025, https://trial.medpath.com/clinical-trial/387959ef2367bb57/nct03567889-efficacy-daromun-neoadjuvant-melanoma-treatment
34. ISRCTN49817477: Radiotherapy combined with immunotherapy in metastatic non-small cell lung cancer patients - ISRCTN Registry, accessed October 3, 2025, https://www.isrctn.com/ISRCTN49817477
35. IMMUNOtherapy and Stereotactic ABlative Radiotherapy - ClinConnect, accessed October 3, 2025, https://clinconnect.io/trials/NCT03705403
36. IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study (IMMUNOSABR2) - ClinicalTrials.gov, accessed October 3, 2025, https://www.clinicaltrials.gov/study/NCT03705403
37. ClinicalTrials.gov: Home, accessed October 3, 2025, https://clinicaltrials.gov/ct2/show/NCT03705403
38. Metastatic Melanoma Stage IV Unknown Status Phase 1 / 2 Trials for Darleukin (DB17157), accessed October 3, 2025, https://go.drugbank.com/indications/DBCOND0068670/clinical_trials/DB17157?phase=1%2C2&status=unknown_status
39. NCT01055522 | Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma | ClinicalTrials.gov, accessed October 3, 2025, https://clinicaltrials.gov/study/NCT01055522
40. A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients | Request PDF - ResearchGate, accessed October 3, 2025, https://www.researchgate.net/publication/335592517_A_phase_II_study_of_the_L19IL2_immunocytokine_in_combination_with_dacarbazine_in_advanced_metastatic_melanoma_patients
41. A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients - PubMed Central, accessed October 3, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11028321/
42. A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination With Dacarbazine for the Therapy of Patients With Metastatic Melanoma - PubMed, accessed October 3, 2025, https://pubmed.ncbi.nlm.nih.gov/22028492/
43. Phase I/II study of the tumor-targeting human L19-IL2 monoclonal antibody-cytokine fusion protein in combination with DTIC in metastatic melanoma patients - ASCO Publications, accessed October 3, 2025, https://ascopubs.org/doi/10.1200/jco.2009.27.15_suppl.9064
44. Study Details | NCT01055522 | Clinical Study Phase II of L19IL2 in ..., accessed October 3, 2025, https://clinicaltrials.gov/ct2/show/NCT01055522
45. Clinical Trial: NCT04362722 - My Cancer Genome, accessed October 3, 2025, https://www.mycancergenome.org/content/clinical_trials/NCT04362722/
46. Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients | Clinical Research Trial Listing - CenterWatch, accessed October 3, 2025, https://www.centerwatch.com/clinical-trials/listings/NCT04362722/intratumoral-administration-of-daromun-in-non-melanoma-skin-cancer-patients
47. ClinicalTrials.gov: Home, accessed October 3, 2025, https://clinicaltrials.gov/ct2/show/NCT04362722
48. Study Details | NCT05329792 | L19IL2/L19TNF in Skin Cancer ..., accessed October 3, 2025, https://clinicaltrials.gov/ct2/show/NCT05329792
49. Darleukin Completed Phase 2 Trials for Malignant Melanoma, Skin Treatment - DrugBank, accessed October 3, 2025, https://go.drugbank.com/drugs/DB17157/clinical_trials?conditions=DBCOND0068673&phase=2&purpose=treatment&status=completed
50. Onfekafusp alfa Completed Phase 2 Trials for Malignant Melanoma, Skin Treatment, accessed October 3, 2025, https://go.drugbank.com/drugs/DB16269/clinical_trials?conditions=DBCOND0068673&phase=2&purpose=treatment&status=completed
51. accessed January 1, 1970, https://clinicaltrials.gov/ct2/show/NCT02076633
52. Darleukin Recruiting Phase 2 Trials for Metastatic Melanoma / Stage III Melanoma Treatment | DrugBank Online, accessed October 3, 2025, https://go.drugbank.com/drugs/DB17157/clinical_trials?conditions=DBCOND0030058%2CDBCOND0028661&phase=2&purpose=treatment&status=recruiting
53. Efficacy of Neoadjuvant Intratumoral Darleukin/Fibromun (L19IL2 + L19TNF) in Patients with Clinical Stage IIIB/C Melanoma (Neo-DREAM) - PubMed, accessed October 3, 2025, https://pubmed.ncbi.nlm.nih.gov/35229218/
54. Nidlegy's approval (FDA, EMA, MHRA and more): How long will you have to wait?, accessed October 3, 2025, https://everyone.org/blog/nidlegy-approval
55. Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial - PMC, accessed October 3, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7296663/
56. darleukin (L19IL2) / Philogen - LARVOL DELTA, accessed October 3, 2025, https://delta.larvol.com/Products/?ProductId=f765c2d2-a1d2-444d-9bb4-8c2e6442c8bd
57. Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins - Oxford Academic, accessed October 3, 2025, https://academic.oup.com/proteincell/article/9/1/15/6768236
58. Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins - Protein&Cell, accessed October 3, 2025, http://www.protein-cell.net/article/doi/10.1007/s13238-017-0408-4
59. Phase I/II study of the tumour-targeting human monoclonal antibody-cytokine fusion protein L19-TNF in patients with advanced solid tumours - PubMed, accessed October 3, 2025, https://pubmed.ncbi.nlm.nih.gov/23160853/
60. Sun Pharma, Philogen Enter Into an Exclusive Distribution, License, and Supply Agreement for Nidlegy in Europe, Australia, and New Zealand - Practical Dermatology, accessed October 3, 2025, https://practicaldermatology.com/news/sun-pharma-philogen-enter-into-an-exclusive-distribution-license-and-supply-agreement-for-nidlegy-in-europe-australia-and-new-zealand/2461752/
61. Submission of Nidlegy™ Marketing Authorization Application Validated by EMA * * * - Philogen, accessed October 3, 2025, https://www.philogen.com/philogen/wp-content/uploads/2024/07/240623_Press_release_Nidlegy_MAA.pdf
62. Sun Pharma's European Partner Withdraws Melanoma Therapy Application from EMA Due to Data Delays - MedPath, accessed October 3, 2025, https://trial.medpath.com/news/ae671848b99b7d6a/sun-pharma-s-european-partner-withdraws-melanoma-therapy-application-from-ema-due-to-data-delays